Related Experiment Videos
Teflon vocal fold augmentation: failures and management in 28 cases
M Nakayama1, C N Ford, D M Bless
1Department of Surgery, University of Wisconsin-Madison 53792-3236.
Summary
Teflon injection for glottic insufficiency has risks. Complications like Teflon granulomas were treated, improving voice quality but not always to normal. Careful patient selection and surgical skill are crucial.
Area of Science:
- Otolaryngology
- Speech-Language Pathology
Background:
- Teflon injection has been a primary treatment for glottic insufficiency for 30 years.
- The reported success and safety of Teflon injection may be overestimated.
- Complications and suboptimal outcomes necessitate re-evaluation of the procedure.
Purpose of the Study:
- To evaluate the outcomes of managing complications arising from Teflon vocal fold augmentation.
- To assess voice quality changes before and after corrective interventions for Teflon-related issues.
- To identify factors influencing the degree of voice improvement after complication management.
Main Methods:
- Retrospective evaluation of 28 patients with poor or complicated Teflon injection results (1984-1991).
- Assessment included acoustic, aerodynamic, videostroboscopic, perceptual, and subjective voice evaluations.
- Management often involved microsurgical removal of Teflon granulomas and addressing subglottic overfilling.
Main Results:
- Most patients presented with Teflon granulomas or subglottic overfilling.
- Voice measures improved post-correction, moving towards normal ranges, but not always achieving complete normalization.
- Significant improvement depended on the extent of Teflon-induced tissue damage and the corrective techniques used.
Conclusions:
- Teflon injection for glottic insufficiency requires careful consideration due to potential complications.
- Microsurgical management can improve voice outcomes in cases of Teflon granulomas and overfilling.
- The procedure should be reserved for clearly indicated cases performed by skilled surgeons, avoiding patients with scarring, atrophy, or mobile folds.